Renata PLC
488.80
BDT
+2.30
+0.47%
Last updated on 19 Jun, 14:31
Today
0.47%
1 Week
1.94%
1 Month
0.60%
6 Month
-25.35%
1 Year
-21.98%
5 Year
-52.37%
Matket Today
Open
485
BDT
Low
485
BDT
High
490
BDT
Volume
6846
Value
0.33
Crore
Trade
245
YCP
486.5
BDT
52W Low
470.1
BDT
52W High
825
BDT
Circuit Low
444
BDT
Circuit Up
529
BDT
Beta (1 Year)
0.78
Financial Indicators
P/E ratio
22.98
EPS (TTM)
21.27
NAV (Q3 2025)
302.49
Total Shares
11.47
Crore
Shot-term loan
1105.87
Crore
Long-term loan
642.40
Crore
Market Capital
5579.98
Crore
Paid-up Capital
114.70
Crore
Authorized Capital
285
Crore
Last AGM Date
05 Dec 2024
Last Record Date
21 Oct 2024
Year End
30-Jun
About Renata PLC
Sector
Pharmaceuticals & Chemicals
Listing Year
1979
renata@renata-ltd.com
Renata Limited, formerly known as Pfizer Limited, is a prominent and rapidly expanding pharmaceutical and animal health product company in Bangladesh. The company commenced operations in 1972 as Pfizer (Bangladesh) Limited. In 1993, Pfizer transferred ownership of its Bangladesh operations to local shareholders, leading to the renaming of the company to Renata Limited. Renata Limited's primary focus areas include human pharmaceuticals and animal health products. In Bangladesh, it stands as the fourth-largest pharmaceutical company and holds the leading position in the market for animal health products. Additionally, Renata's products are exported to various countries, including Afghanistan, Belize, Cambodia, Ethiopia, Guyana, Honduras, Hong Kong, Kenya, Malaysia, Myanmar, Nepal, Philippines, Sri Lanka, Thailand, the United Kingdom, and Vietnam. The company is listed on the Dhaka Stock Exchange, boasting a market capitalization exceeding USD $1 billion. Renata Limited operates ten manufacturing facilities across three manufacturing sites, and its product distribution is facilitated by 19 depots spread throughout the country. The company's significant presence and diverse product portfolio contribute to its position as a key player in the pharmaceutical and animal health industries in Bangladesh and beyond.